Source: Eur Respir J 2001; 17: 1-3
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Galie N.. Do we need controlled clinical trials in pulmonary arterial hypertension?. Eur Respir J 2001; 17: 1-3

Member's Comments

No comment yet.

Related content which might interest you: End-points and clinical trial design in pulmonary arterial hypertension: have we made progress? Source: Eur Respir J 2009; 34: 231-242 Year: 2009 Interpreting risk reduction in clinical trials for pulmonary arterial hypertension Source: Eur Respir Rev, 27 (148) 180020; 10.1183/16000617.0020-2018 Year: 2018 New perspectives in long-term outcomes in clinical trials of pulmonary arterial hypertension Source: Eur Respir Rev 2013; 22: 495-502 Year: 2013 Clinical trial design and new therapies for pulmonary arterial hypertension Source: Eur Respir J, 53 (1) 1801908; 10.1183/13993003.01908-2018 Year: 2019 Clinical trials in pulmonary arterial hypertension: what they tell us Source: ERS Course 2020 - Pulmonary hypertension and pulmonary vascular disease Year: 2020 Clinical trials in pulmonary arterial hypertension: what do they tell us Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2017 Clinical trials in pulmonary arterial hypertension: what do they tell us Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease Year: 2018 Standardised exercise training is feasible, safe and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension - results from a large European multicentre randomised controlled trial Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension Year: 2020 Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value Source: Eur Respir J 2007; 29: 432-434 Year: 2007 Incidence of subdural hematoma in patients with pulmonary arterial hypertension (PAH) in two randomized controlled clinical trials Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012 Pulmonary arterial hypertension patients underrepresented in clinical trials – Are they different? Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Effect of macitentan on haemodynamics in SERAPHIN, a randomised controlled trial in pulmonary arterial hypertension (PAH) Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 The future of treatment for pulmonary arterial hypertension Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2017 The future of treatment for pulmonary arterial hypertension Source: School Course 2014 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2014 The future of treatment for pulmonary arterial hypertension Source: School Course 2012 - Pulmonary hypertension and pulmonary vascular disease Year: 2012 The future of treatment for pulmonary arterial hypertension Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease Year: 2018 Effect of long-term oxygen therapy on exercise capacity and quality of life in exercise-desaturating patients with pulmonary arterial or chronic thromboembolic pulmonary hypertension: a randomized-sham-controlled cross-over trial Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 Long-term safety and clinical effects of riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: Interim analysis of a phase II extension study Source: Annual Congress 2010 - Pulmonary hypertension updates Year: 2010 Bosentan treatment for pulmonary arterial hypertension related to congenital heart disease: real-world clinical experience in Spain Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009